Compare CDMOs with comprehensive analytical services for release testing, stability, method development, and characterization. Filter by testing type, accreditation, and capacity.
873 companies listed
If the data isn't GMP, it doesn't count toward release or a filing — that's the whole game with analytical services. Every batch you release and every submission you make rests on analytical data: identity, assay, impurities, dissolution, sterility. A contract lab produces the evidence that your product meets spec. Cheap, non-GMP numbers can't be used for either purpose, so verify the quality system first. What are you actually buying? Release and stability testing under ICH conditions, method development and validation per ICH Q2, and the scientific depth to run down an out-of-specification result instead of just reporting it. Data integrity is now a top FDA inspection finding, so ask how they handle audit trails and chromatographic review. For biologics, confirm characterization and comparability capability, not just small molecule HPLC. 873 CDMOs here list analytical services. Compare them by testing scope, accreditation, and molecule type.
Analytical services underpin every stage of pharmaceutical development and manufacturing. From raw material testing through in-process controls to finished product release, analytical data provides the evidence that a drug product meets its specifications. GMP analytical laboratories must operate under validated methods, calibrated equipment, and documented procedures.
CDMOs offering analytical services range from full-service integrated organizations (manufacturing + analytics) to specialized contract testing laboratories. The most valuable analytical partners offer: method development and validation, release and stability testing, regulatory filing support (CTD Module 3), and the scientific depth to troubleshoot out-of-specification results.
France
X'PROCHEM is a French biotech company founded in 2012, specializing in chemical protein synthesis for therapeutic and diagnostic use. They design and produce therapeutic proteins using a proprietary robotic molecular assembly platform that builds proteins amino acid by amino acid, enabling complete structural control for proteins that cannot be produced by biological methods.
Germany
YUMAB GmbH is a German biotechnology company specializing in contract research for the discovery and development of fully human therapeutic antibodies. They provide antibody discovery, engineering, humanization, and characterization services using proprietary human-derived antibody libraries (>10^11) and in-vitro selection technology.
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.
China
Zhejiang Langhua Pharmaceutical Co., Ltd. is a comprehensive CDMO subsidiary of Viva Biotech Holdings, specializing in small molecule contract development and manufacturing. Viva Biotech acquired Langhua for RMB 2,560 million ($368M) to build out their CDMO service chain capabilities. Langhua offers CMC development, API synthesis, and formulation services from pre-clinical through commercial scale. They have completed numerous CDMO cases and have a subsidiary Ningbo Nuobai Pharmaceutical for additional capacity. The company is FDA-registered (FEI 3005289386) and has passed an FDA on-site cGMP inspection, with 3 total FDA inspections (1 NAI, 2 VAI, 0 OAI). They market themselves explicitly as a CDMO offering end-to-end services from CMC through API to formulation manufacturing. No website text was available (empty), so classification relies on search results and regulatory data.